Open- | Close- |
Vol / Avg.31.000 / 310.509K | Mkt Cap33.312M |
Day Range- - - | 52 Wk Range0.458 - 1.760 |
Homology Medicines Stock (NASDAQ: FIXX) stock price, news, charts, stock research, profile.
Open- | Close- |
Vol / Avg.31.000 / 310.509K | Mkt Cap33.312M |
Day Range- - - | 52 Wk Range0.458 - 1.760 |
Q4 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.420 | -0.570 | -0.1500 | ||||
REV | 500.000K | 0 | -500.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-07-28 | Baird | Madhu Kumar | Downgrades | OutperformNeutral | Lowers | 9.00 | 1.50 |
2023-05-15 | HC Wainwright & Co. | Patrick Trucchio | Reiterates | BuyBuy | Maintains | - | 20.00 |
2023-05-12 | Credit Suisse | Richard Law | Reiterates | NeutralNeutral | Maintains | - | 2.00 |
2023-05-12 | Chardan Capital | Matthew Barcus | Maintains | BuyBuy | Lowers | 8.00 | 7.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
FIXX | Homology Medicines | 3.27% | 33.3M |
CLRB | Cellectar Biosciences | 1.13% | 32.9M |
PHXM | PHAXIAM Therapeutics | 9.37% | 29.8M |
COEP | Coeptis Therapeutics | 1.91% | 36.2M |
BOLT | Bolt Biotherapeutics | 0% | 34.2M |
You can purchase shares of Homology Medicines (NASDAQ: FIXX) through any online brokerage.
Other companies in Homology Medicines’s space includes: Cellectar Biosciences (NASDAQ:CLRB), PHAXIAM Therapeutics (NASDAQ:PHXM), Coeptis Therapeutics (NASDAQ:COEP), Bolt Biotherapeutics (NASDAQ:BOLT) and Eledon Pharma (NASDAQ:ELDN).
The latest price target for Homology Medicines (NASDAQ: FIXX) was reported by Baird on Friday, July 28, 2023. The analyst firm set a price target for 1.50 expecting FIXX to rise to within 12 months (a possible 160.87% upside). 5 analyst firms have reported ratings in the last year.
The stock price for Homology Medicines (NASDAQ: FIXX) is $0.575 last updated December 8, 2023 at 12:23 PM UTC.
There is no dividend information for Homology Medicines.
Homology Medicines’s Q4 earnings are confirmed for Thursday, March 7, 2024.
There is no upcoming split for Homology Medicines.
Homology Medicines is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.